» Articles » PMID: 22090136

Cholesterol-rich Microdomains As Docking Platforms for Respiratory Syncytial Virus in Normal Human Bronchial Epithelial Cells

Overview
Journal J Virol
Date 2011 Nov 18
PMID 22090136
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Respiratory syncytial virus (RSV) is one of the major causes of respiratory infections in children, and it is the main pathogen causing bronchiolitis in infants. The binding and entry mechanism by which RSV infects respiratory epithelial cells has not yet been determined. In this study, the earliest stages of RSV infection in normal human bronchial epithelial cells were probed by tracking virions with fluorescent lipophilic dyes in their membranes. Virions colocalized with cholesterol-containing plasma membrane microdomains, identified by their ability to bind cholera toxin subunit B. Consistent with an important role for cholesterol in RSV infection, cholesterol depletion profoundly inhibited RSV infection, while cholesterol repletion reversed this inhibition. Merger of the outer leaflets of the viral envelope and the cell membrane appeared to be triggered at these sites. Using small-molecule inhibitors, RSV infection was found to be sensitive to Pak1 inhibition, suggesting the requirement of a subsequent step of cytoskeletal reorganization that could involve plasma membrane rearrangements or endocytosis. It appears that RSV entry depends on its ability to dock to cholesterol-rich microdomains (lipid rafts) in the plasma membrane where hemifusion events begin, assisted by a Pak1-dependent process.

Citing Articles

How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody.

Marcink T, Zipursky G, Sobolik E, Golub K, Herman E, Stearns K Nat Commun. 2024; 15(1):8831.

PMID: 39396053 PMC: 11470942. DOI: 10.1038/s41467-024-53082-y.


Cholesterol-rich lysosomes induced by respiratory syncytial virus promote viral replication by blocking autophagy flux.

Chen L, Zhang J, Xu W, Chen J, Tang Y, Xiong S Nat Commun. 2024; 15(1):6311.

PMID: 39060258 PMC: 11282085. DOI: 10.1038/s41467-024-50711-4.


Identification and Analysis of Biomarkers Associated with Lipophagy and Therapeutic Agents for COVID-19.

Wu Y, Wu Z, Jin Q, Liu J, Xu P Viruses. 2024; 16(6).

PMID: 38932215 PMC: 11209609. DOI: 10.3390/v16060923.


Detailed analysis of low temperature inactivation of respiratory syncytial virus.

Kitai Y, Watanabe O, Ohmiya S, Kisu T, Ota R, Kawakami K Sci Rep. 2024; 14(1):11823.

PMID: 38783052 PMC: 11116427. DOI: 10.1038/s41598-024-62658-z.


Exploring the secrets of virus entry: the first respiratory syncytial virus carrying beta lactamase.

De Avila-Arias M, Villarreal-Camacho J, Cadena-Cruz C, Hurtado-Gomez L, Costello H, Rodriguez A Front Microbiol. 2024; 15:1339569.

PMID: 38455070 PMC: 10919290. DOI: 10.3389/fmicb.2024.1339569.


References
1.
Viaud J, Peterson J . An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther. 2009; 8(9):2559-65. PMC: 2782767. DOI: 10.1158/1535-7163.MCT-09-0102. View

2.
Lopez J, Bustos R, Orvell C, Berois M, Arbiza J, Melero J . Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol. 1998; 72(8):6922-8. PMC: 109907. DOI: 10.1128/JVI.72.8.6922-6928.1998. View

3.
Umashankar M, Martin C, Liao M, Reilly B, Guo A, Taylor G . Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol. 2008; 82(18):9245-53. PMC: 2546879. DOI: 10.1128/JVI.00975-08. View

4.
Razinkov V, Huntley C, Ellestad G, Krishnamurthy G . RSV entry inhibitors block F-protein mediated fusion with model membranes. Antiviral Res. 2002; 55(1):189-200. DOI: 10.1016/s0166-3542(02)00050-5. View

5.
Malhotra R, Ward M, Bright H, Priest R, Foster M, Hurle M . Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect. 2003; 5(2):123-33. DOI: 10.1016/s1286-4579(02)00079-5. View